Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia

Details

Serval ID
serval:BIB_3BFB78454845
Type
Article: article from journal or magazin.
Collection
Publications
Title
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia
Journal
J Clin Psychopharmacol
Author(s)
Lerond J., Lothe A., Ryvlin P., Bouvard S., d'Amato T., Ciumas C., Dalery J., Poulet E., Saoud M.
ISSN
1533-712X (Electronic)
ISSN-L
0271-0749
Publication state
Published
Issued date
02/2013
Volume
33
Number
1
Pages
84-9
Language
english
Notes
Lerond, Jerome
Lothe, Amelie
Ryvlin, Philippe
Bouvard, Sandrine
d'Amato, Thierry
Ciumas, Carolina
Dalery, Jean
Poulet, Emmanuel
Saoud, Mohamed
eng
Comparative Study
Research Support, Non-U.S. Gov't
J Clin Psychopharmacol. 2013 Feb;33(1):84-9. doi: 10.1097/JCP.0b013e31827b97a6.
Abstract
To investigate the impact of various antipsychotic drugs on the 5-HT1A serotoninergic system, we performed a [F]4-(2-methoxyphenyl)-1-[2-(N-2-pirydynyl)-p-luorobenzamido]-ethyl-piperazine PET study in 19 schizophrenic patients treated with either aripiprazole, which has a partial agonist activity at 5-HT1A receptors, or second-generation antipsychotics (SGA) (olanzapine or risperidone), which do not demonstrate such property. We used a simplified reference tissue model to generate parametric images of [F]MPPF-binding potential (BPND). A significant reduction of [F]MPPF BPND was found in treated schizophrenic patients compared to age- and sex-matched healthy subjects. These modifications were mainly localized in the frontal and orbitofrontal cortex and may reflect either the pathophysiology of schizophrenia or medication effects. The schizophrenic patients treated with aripiprazole showed a reduction of global [F]MPPF BPND compared with healthy subjects and schizophrenic patients with SGA treatment. In addition, compared with matched controls, the reduction of regional [F]MPPF BPND was more marked in the schizophrenic patients treated with aripiprazole compared with those receiving SGA treatment, possibly reflecting the partial agonist of aripiprazole activity at 5-HT1A receptors.
Keywords
Adult, Analysis of Variance, Antipsychotic Agents/*therapeutic use, Aripiprazole, Benzodiazepines/metabolism/*therapeutic use, Case-Control Studies, Cerebral Cortex/diagnostic imaging/*drug effects/metabolism, Drug Partial Agonism, Female, Humans, Magnetic Resonance Imaging, Male, Piperazines/metabolism/*therapeutic use, Positron-Emission Tomography, Pyridines, Quinolones/metabolism/*therapeutic use, Radiopharmaceuticals, Receptor, Serotonin, 5-HT1A/*drug effects/metabolism, Risperidone/metabolism/*therapeutic use, Schizophrenia/diagnosis/diagnostic imaging/*drug therapy/metabolism, Schizophrenic Psychology, Treatment Outcome, Young Adult
Pubmed
Create date
29/11/2018 12:36
Last modification date
20/08/2019 13:32
Usage data